{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:35:11Z","timestamp":1774539311151,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jad.2019.03.006","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T20:03:31Z","timestamp":1551729811000},"page":"330-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report"],"prefix":"10.1016","volume":"250","author":[{"given":"Tao","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2019.03.006_bib0001","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1192\/bjp.165.6.728","article-title":"Extrapyramidal symptoms with selective serotonin reuptake inhibitors","volume":"165","author":"Arya","year":"1994","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.03.006_bib0002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1176\/ajp.2007.164.7.1121a","article-title":"Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants","volume":"164","author":"Ashton","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.03.006_bib0003","first-page":"266","article-title":"Duloxetine-related galactorrhea and restless legs syndrome: a case report","volume":"25","author":"Belli","year":"2013","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.jad.2019.03.006_bib0004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinemia: incidence, mechanisms and management","volume":"24","author":"Coker","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2019.03.006_bib0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism","volume":"29","author":"De Bartolomeis","year":"2015","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.jad.2019.03.006_bib0006","first-page":"2635","article-title":"Aripiprazole: from pharmacological profile to clinical use","volume":"13","author":"Di Sciacio","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2019.03.006_bib0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.npp.1300412","article-title":"From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions","volume":"29","author":"Emiliano","year":"2004","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.jad.2019.03.006_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2019.03.006_bib0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000126134","article-title":"Involvement of 5-HT1, 5-HT2, and 5-HT3 receptors in the mediation of the prolactin response to serotonin and 5-hydroxytryptophan","volume":"55","author":"Jorgensen","year":"1992","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.jad.2019.03.006_bib0010","doi-asserted-by":"crossref","first-page":"e82749","DOI":"10.1371\/journal.pone.0082749","article-title":"Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2019.03.006_bib0011","first-page":"200","article-title":"Galactorrhea during duloxetine treatment: a case report","volume":"22","author":"Korkmaz","year":"2011","journal-title":"Turk. Psikiyatri. Derg."},{"key":"10.1016\/j.jad.2019.03.006_bib0012","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic Aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.jad.2019.03.006_bib0013","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tips.2007.06.002","article-title":"GPCR functional selectivity has therapeutic impact","volume":"28","author":"Mailman","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.jad.2019.03.006_bib0014","first-page":"4","article-title":". Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials","volume":"27","author":"Meng","year":"2015","journal-title":"Shanghai Arch. Psychiatry"},{"key":"10.1016\/j.jad.2019.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jad.2019.03.006_bib0016","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4088\/JCP.v67n0612","article-title":". Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine","volume":"67","author":"Papakostas","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.03.006_bib0017","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4306\/pi.2017.14.3.368","article-title":"Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study","volume":"14","author":"Park","year":"2017","journal-title":"Psychiatry Investig."},{"key":"10.1016\/j.jad.2019.03.006_bib0018","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1210\/endo.133.2.8344205","article-title":". Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1C\/2 receptors","volume":"133","author":"Rittenhouse","year":"1993","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.jad.2019.03.006_bib0019","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1176\/appi.neuropsych.12030071","article-title":"Mirtazapine-induced galactorrhea: a case report","volume":"25","author":"Schroeder","year":"2013","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2019.03.006_bib0020","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2019.03.006_bib0021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/00912700022008810","article-title":"Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor","volume":"40","author":"Sharma","year":"2000","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jad.2019.03.006_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/psychiatry.IndianJPsychiatry_317_17","article-title":"Galactorrhea with antidepressants: a case series","volume":"60","author":"Suthar","year":"2018","journal-title":"Indian J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2019.03.006_bib0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.9740\/mhc.2016.07.185","article-title":"Management of antipsychotic-induced hyperprolactinemia","volume":"6","author":"Tewksbury","year":"2016","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.jad.2019.03.006_bib0024","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/11595660-000000000-00000","article-title":". Serotonin reuptake inhibitors and hyperprolactinaemia: a case\/non-case study in the French pharmacovigilance database","volume":"34","author":"Trenque","year":"2011","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2019.03.006_bib0025","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jad.2019.03.006_bib0026","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2174\/1570159X15666170413115754","article-title":"Aripiprazole, a drug that displays partial agonism and functional selectivity","volume":"15","author":"Tuplin","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.jad.2019.03.006_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2019.03.006_bib0028","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.npp.1301071","article-title":"Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways","volume":"32","author":"Urban","year":"2007","journal-title":"Neuropsychopharmac"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718321657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032718321657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T14:24:17Z","timestamp":1556288657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032718321657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":28,"alternative-id":["S0165032718321657"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.03.006","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}